Financial News · Live Terminal

Page 189 of 316

Piper Sandler Downgrades Roblox to Neutral From Overweight, Adjusts Price Target to $50 From $100

Roblox (RBLX) has an average rating of overweight and mean price target of $67.31, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$RBLX

Research56d ago

Leerink Upgrades Twist Bioscience to Outperform From Market Perform, Adjusts Price Target to $70 From $55

Twist Bioscience (TWST) has an average rating of buy and mean price target of $65.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TWST

Research56d ago

Research Alert: CFRA Maintains Buy Opinion On Shares Of Pinterest

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our target to $28 from $19, on a higher P/E of 13.4x our 2027 EPS view, below peers and historical multiples to reflect uncertainties around AI competitive dynamics. After it posted better-than-expected Q1 results and a strong Q2 guidance, we raise our 2026 EPS view to $1.87 from $1.75 and 2027's to $2.09 from $1.90. We see improving international monetization as the primary growth driver near term (Rest of World and Europe saw 59% and 27% revenue growth in Q1) while the company's AI investments are delivering greater results for advertisers. PINS's recommendation engine model improved search fulfillment by 180 basis points in Q1 while Performance+ campaigns now account for 30% of lower-funnel revenue with adopters growing spend at twice the rate of non-adopters. The now completed tvScientific deal also injects a new growth opportunity into the faster growing Connected TV market. We believe PINS's low teens P/E undervalues these growth initiatives and a more aggressive cash return to investors.

$PINS

Research56d ago

BTIG Research Downgrades Global Business Travel to Neutral

Global Business Travel Group (GBTG) has an average rating of overweight and mean price target of $9.75, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$GBTG

Research56d ago

HSBC Upgrades Banco Macro to Buy From Hold, Adjusts Price Target to $85 From $80

Banco Macro (BMA) has an average rating of buy and mean price target of $116.07, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$BMA

Research56d ago

BofA Securities Downgrades Inspire Medical Systems to Neutral From Buy, $53 Price Target

Inspire Medical Systems (INSP) has an average rating of Hold and mean price target of $55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$INSP

Research56d ago

UBS Downgrades Fermi to Neutral From Buy, Adjusts Price Target to $6 From $8

Fermi Inc. (FRMI) has an average rating of Buy and mean price target of $21.56, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$FRMI

Research56d ago

Needham Downgrades Esperion Therapeutics to Hold From Buy

Esperion Therapeutics (ESPR) has an average rating of Hold and mean price target of $3.19, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ESPR

Research56d ago

Wedbush Initiates Sionna Therapeutics at Outperform With $53 Price Target

Sionna Therapeutics (SION) has an average rating of buy and mean price target of $50.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SION

Research56d ago

Seaport Initiates ACM Research at Buy With $75 Price Target

ACM Research (ACMR) has an average rating of buy and mean price target of $71.14, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ACMR

Research56d ago

Chardan Initiates Climb Bio at Buy With $22 Price Target

Climb Bio (CLYM) has an average rating of buy and mean price target of $16.69, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CLYM

Research56d ago

Zephirin Upgrades Pinterest to Buy From Sell, Raises Price Target to $30 From $17, Keeps High Risk

Pinterest (PINS) has an average rating of overweight and mean price target of $26.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$PINS

Research56d ago

Piper Sandler Downgrades Tractor Supply to Neutral From Overweight, Adjusts PT to $36 From $51

Tractor Supply Company (TSCO) has an average rating of overweight and mean price target of $47.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TSCO

Research56d ago

Seaport Global Initiates Applied Materials at Buy With $500 Price Target

Applied Materials (AMAT) has an average rating of buy and mean price target of $435.13, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AMAT

Research56d ago

Seaport Global Initiates Lam Research at Buy With $300 Price Target

Lam Research (LRCX) has an average rating of overweight and mean price target of $314.31, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$LRCX

Research56d ago

Research Alert: CFRA Maintains Buy Opinion On Adss Of Anheuser-busch Inbev

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price for Anheuser-Busch InBev (ABI) is raised to USD94 (from USD92). This implies a 20.8x 2026 P/E, a premium to the industry forward average of 12.5x and its five-year historical average of 17.6x. Our relative valuation reflects ABI's improved financial position, both in terms of profitability and indebtedness, which should translate into meaningful profit. We like ABI for its industry-leading margins (LTM EBIT margin: 26.4% vs. peers' average: 17.4%), which is expected to gain further on improving volume outlook. We raise our 2026 EPADS estimate to USD4.50 (from USD4.41) and 2027's to USD5.08 (from USD4.95). We think that forex transactional headwinds will continue to be an issue moving forward, but will not deter ABI from sustaining its growth momentum given evidence of strong volume recovery and positive development across its strategic drivers. We remain confident in ABI's growth trajectory given its global portfolio strength and resilient market share across its key markets.

$BUD

Research56d ago

DBS Group Research Upgrades SIA Engineering to Buy from Hold, Adjusts Price Target to SG$3.80 from SG$4

SGX:S59

Research56d ago

Bob Capital Markets Downgrades ACC to Hold from Buy; Price Target is INR1,595

ACC (NSE:ACC) has an average rating of overweight and mean price target of 1,656.64 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

BOM:500410NSE:ACC

Research56d ago

Research Alert: Fme Q1: Currency Headwinds Drag, U.s. Treatment Growth Remains Challenged

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Q1 2026 revenue fell 5.5% reported to EUR4,612M, in line with consensus, though organic growth remained positive at 3.9% (Q4: +8.2%). Operating margin (excluding special items) improved to 10.1% from 9.4% prior year, supported by FME25+ savings of EUR50M, while reported operating income declined 14% due to EUR181M in transformation costs. Care Delivery posted strongest performance with organic revenue +6.1% and margin up 1.8%-pts to 12.1%, benefiting from TDAPA reimbursement tailwinds, though U.S. same market treatment continued declining (-0.4%). FME reaffirmed its 2026 guidance for broadly flat revenue and operating income at constant currencies, expecting stronger 1H 2026 before TDAPA benefits phase out in 2H. While we are positive on sustained FME25+ cost savings, the timeline for U.S. same market volume recovery remains uncertain, which we see as a key concern. FME expects flat U.S. treatment growth in 2026 but provided no specific recovery timeline, suggesting elevated uncertainty remains, in our view.

$FMS

Research56d ago

Research Alert: Ab Inbev Q1 Tops Estimates; Corona Momentum, Volume Recovery Support Outlook

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ABI reported Q1 2026 organic revenue growth of 5.8%, beating consensus of 3.0%, supported by revenue per hectoliter growth of 4.5% and a volume increase of 0.8% vs. expected decline of 0.5%. Underlying EPS of USD0.97 surpassed consensus of USD0.89 and the prior year's USD0.81, representing the highest Q1 performance in company history. We believe ABI's megabrands momentum, with combined revenues growing 8.2%, led by Corona's 16% growth outside its home market, demonstrates competitive positioning strength with market share gains in 75% of its markets. Management maintained 2026 EBITDA growth guidance of 4-8%, in line with its medium-term outlook and consensus of 5.1%, with capex expected at USD3.5-4.0B. The Beyond Beer segment accelerated with 37% revenue growth, while gross margin expanded 76 bps to 56.6% despite EBITDA margin contracting 15 bps due to increased marketing investments. We remain confident in ABI's growth trajectory given its global portfolio strength and resilient market positioning.

$BUD

Showing 3761-3780 of 6317